Evidence map›Paper›PMID 26510563›Full record

ArticleWorld journal of surgery2016

Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Population-Based Study.

Naris Nilubol, Dhaval Patel, Electron Kebebew

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Review
  10. American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2020
    Review
  11. [Surgery of adrenal diseases].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2020
    Article
  12. Article
  13. [Resection strategies for adrenocortical carcinoma].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2019
    Review
  14. [Surgical strategies for non-metastatic adrenocortical carcinoma].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2018
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Naris NilubolEndocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Rm. 3-5840, Bethesda, MD, 20892, USA. niluboln@mail.nih.gov.
Dhaval PatelEndocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Rm. 3-5840, Bethesda, MD, 20892, USA.
Electron KebebewEndocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Rm. 3-5840, Bethesda, MD, 20892, USA.
Center for Cancer Research · USNational Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA recent study suggested a survival benefit in patients with adrenocortical carcinoma (ACC) who had undergone lymphadenectomy. The objective of this study was to study the effect of lymphadenectomy on the survival rates of patients with ACC.

methodsData from adult patients with histology-proven ACC from the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 Registries (1973-2011) were analyzed to assess the impact of lymphadenectomy (≥4 lymph nodes removed) on disease-specific survival (DSS).

resultsOf 1525 patients with ACC, 45% were male. 36, 20, and 44% of patients presented with localized, regional, and distant metastatic diseases, respectively. 8% of patients (n = 67/802) underwent lymphadenectomy. We observed a higher rate of lymphadenectomy performed in patients with regional disease [locally advanced tumors (stage T3 and T4) and/or lymph node metastasis] and distant metastasis than in those with localized tumors (12.4% and 12.0 vs. 5.1, respectively, p < 0.01) and in patients with primary tumor sizes >10 cm (12.4 vs. 4.2 %, p < 0.01). Lymph node metastasis was present in 12.8% (19.2% in locally advanced ACC). A lymphadenectomy was not associated with improved DSS on univariate analysis (p = 0.30), regardless of tumor size or staging. Independent prognostic factors included: ages ≥60 years (p < 0.01, HR 1.70), lymph node metastasis (p < 0.01, HR 1.7), distant metastasis (p < 0.01, HR 5.6), complete resection of tumor (p < 0.01, HR 0.47), and debulking surgery (p < 0.01, HR 0.49).

conclusionA lymphadenectomy is not commonly performed in patients with ACC in the U.S. Although we found no survival benefit in this cohort with a low rate of lymphadenectomy, a lymphadenectomy may be considered in patients with locally advanced tumors (T3 and T4) due to a higher rate of lymph node metastasis.

Indexed as

Lymph Node ExcisionSEER ProgramAdrenal Cortex NeoplasmsAdrenocortical CarcinomaAdultFemaleHumansLymphatic MetastasisLymph NodesMaleMiddle AgedSurvival RateUnited StatesYoung Adult

Identifiers

PMID26510563
OpenAlexW2219799372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.